Sinus bradycardia associated with daclizumab in liver transplant recipients: report of 3 cases.
Exp Clin Transplant
; 6(1): 80-3, 2008 Mar.
Article
em En
| MEDLINE
| ID: mdl-18405250
Daclizumab is a commonly used immunosuppressive agent for prophylaxis of solid organ rejection. Although rare, the cardiovascular adverse effects of daclizumab include sinus tachycardia, hypotension, and hypertension. Here, we report 3 patients who developed significant and prolonged sinus bradycardia after receiving daclizumab following orthotopic liver transplant. Daclizumab should be considered a possible cause of bradycardia following its administration in orthotopic liver transplant.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Bradicardia
/
Imunoglobulina G
/
Transplante de Fígado
/
Imunossupressores
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article